| Recruiting | A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) NCT07348237 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Rena NCT07426380 | Eli Lilly and Company | Phase 1 |
| Recruiting | A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function NCT07315360 | Pfizer | Phase 1 |
| Recruiting | A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls NCT07217886 | Shionogi | Phase 1 |
| Active Not Recruiting | A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participant NCT07165015 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With C NCT07124403 | Centre Hospitalier Universitaire de Besancon | — |
| Completed | Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls NCT07012005 | Shionogi | Phase 1 |
| Recruiting | Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalir NCT07154901 | AstraZeneca | Phase 1 |
| Recruiting | Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes NCT07017933 | 3ive Labs | N/A |
| Completed | An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Mod NCT06962774 | Alumis Inc | Phase 1 |
| Completed | Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function NCT07076030 | Zealand Pharma | Phase 1 |
| Recruiting | Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal NCT06911320 | Atea Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010) NCT06814119 | Merck Sharp & Dohme LLC | Phase 1 |
| Withdrawn | Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to M NCT05541159 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD62 NCT06845813 | AstraZeneca | Phase 1 |
| Completed | A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerabilit NCT06742762 | AstraZeneca | Phase 1 |
| Completed | A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Sta NCT06723535 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) NCT06643377 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Imp NCT06661733 | AstraZeneca | Phase 1 |
| Completed | A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe R NCT06693765 | AstraZeneca | Phase 1 |
| Terminated | AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairme NCT06611423 | AstraZeneca | Phase 1 |
| Terminated | A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impa NCT06639087 | AstraZeneca | Phase 1 |
| Recruiting | Effect of Renal Impairment on Enpatoran Pharmacokinetics NCT06589713 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| Completed | Ultra-low Dose Contrast for Endovascular Procedures NCT06835127 | Attikon Hospital | — |
| Completed | A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerabilit NCT06592482 | AstraZeneca | Phase 1 |
| Completed | Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects NCT06527677 | Antabio | Phase 1 |
| Completed | A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) NCT06295796 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function NCT06496217 | MBX Biosciences | Phase 1 |
| Active Not Recruiting | Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impair NCT06671444 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Completed | A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems NCT06352411 | Boehringer Ingelheim | Phase 1 |
| Active Not Recruiting | Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystec NCT06408597 | Nazmy Edward Seif | N/A |
| Completed | Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Particip NCT03896750 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment NCT06318676 | Celgene | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg R NCT06397872 | Madrigal Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Fu NCT06037031 | Pfizer | Phase 1 |
| Completed | Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Imp NCT07033182 | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd | Phase 1 |
| Completed | A Study of TAK-279 in Adults With or Without Kidney Problems NCT05992155 | Takeda | Phase 1 |
| Completed | Assessment of Renal Function by Multiparametric MRI NCT06407375 | University of Zurich | EARLY_Phase 1 |
| Completed | A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Comp NCT05940402 | AbbVie | Phase 1 |
| Completed | A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod NCT05927415 | argenx | Phase 1 |
| Terminated | Study of GBT021601 in Participants With Renal Impairment NCT05878704 | Pfizer | Phase 1 |
| Completed | A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment NCT05865171 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Completed | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 NCT05844228 | Vir Biotechnology, Inc. | Phase 1 |
| Withdrawn | A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, a NCT05406219 | Bayer | Phase 1 |
| Completed | Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment NCT05793450 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010 NCT05812417 | Dong-A ST Co., Ltd. | Phase 1 |
| Unknown | A Study to Evaluate the Pharmacokinetics of HSK21542 in Subjects With Renal Impairment NCT05947097 | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir NCT05731804 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 NCT05631938 | Achieve Life Sciences | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment NCT05916573 | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 |
| Terminated | Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment NCT05552859 | Sanofi | Phase 4 |
| Completed | Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function NCT05711381 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Recruiting | Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participan NCT06708520 | Noucor Health S.A. | Phase 1 |
| Completed | Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function NCT05515458 | Chipscreen Biosciences, Ltd. | Phase 1 |
| Completed | Study of AT-527 in Subjects With Normal and Impaired Renal Function NCT05618314 | Atea Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Role Of Serum Adiponectin In The Ealy Detection Of Renal Impairment In Patients With Non Alcoholic Fatty Liver NCT05556135 | Assiut University | — |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Norma NCT05489614 | Amgen | Phase 1 |
| Terminated | A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction NCT05510245 | Pfizer | Phase 1 |
| Completed | A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well NCT05495581 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out NCT05515432 | Bayer | Phase 1 |
| Completed | A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants NCT05363215 | Shionogi | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment NCT05497297 | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 |
| Completed | A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021) NCT04994522 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) NCT05386758 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543 NCT05468749 | Concert Pharmaceuticals | Phase 1 |
| Completed | To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compare NCT05404542 | Cerevel Therapeutics, LLC | Phase 1 |
| Unknown | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received O NCT05298683 | Hellenic Society of Hematology | Phase 2 |
| Completed | Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects NCT05368935 | Genfit | Phase 1 |
| Unknown | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by I NCT05147493 | Hellenic Society of Hematology | Phase 2 |
| Completed | Fruquintinib Renal Impairment Study NCT05216354 | Hutchmed | Phase 1 |
| Completed | Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Im NCT05282030 | Sanofi | Phase 1 |
| Completed | A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment NCT05200286 | F2G Biotech GmbH | Phase 1 |
| Completed | A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Pa NCT04949438 | AstraZeneca | Phase 1 |
| Completed | A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People NCT05117294 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impair NCT05099445 | Incyte Corporation | Phase 1 |
| Completed | A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairm NCT05112419 | AstraZeneca | Phase 1 |
| Completed | Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function NCT05032235 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impair NCT05086107 | BioVersys AG | Phase 1 |
| Unknown | Bowel Cleansing With Renal Impairment NCT05349851 | Marco Antonio Alvarez Gonzalez | — |
| Completed | The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics NCT05004311 | Viatris Innovation GmbH | Phase 1 |
| Completed | A Study of JNJ-73763989 in Adult Participants With Renal Impairment NCT04963738 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment NCT05673603 | Insmed Incorporated | Phase 1 |
| Completed | Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participa NCT04810598 | AbbVie | Phase 1 |
| Completed | Study of ALXN2050 in Participants With Renal Impairment NCT04623710 | Alexion Pharmaceuticals, Inc. | Phase 1 |
| Completed | Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and i NCT04909853 | Pfizer | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment NCT04859439 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Completed | Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function NCT04865393 | Spero Therapeutics | Phase 1 |
| Completed | Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD NCT04565171 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants NCT04616677 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Surufatinib Renal Impairment Study NCT04755088 | Hutchison Medipharma Limited | Phase 1 |
| Terminated | Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy NCT04678505 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment NCT04646889 | Arthrosi Therapeutics | Phase 1 |
| Completed | STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AN NCT04616027 | Pfizer | Phase 1 |
| Completed | PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With NCT04656795 | Tanabe Pharma America, Inc. | Phase 1 |
| Completed | A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared NCT04476849 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Fu NCT04446507 | Zydus Therapeutics Inc. | Phase 1 |
| Terminated | A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 NCT04426357 | Janssen Pharmaceutica N.V., Belgium | Phase 1 |
| Completed | Renal Impairment Study of PF-06700841 NCT04260464 | Pfizer | Phase 1 |
| Completed | Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment NCT04469907 | AstraZeneca | Phase 1 |
| Completed | A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys NCT04056455 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Kidney Affection in Non Alcaholic Fatty Liver Diseases NCT04273230 | Assiut University | — |
| Unknown | Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function NCT04249908 | IlDong Pharmaceutical Co Ltd | Phase 1 |
| Completed | Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Fun NCT04178447 | Zealand Pharma | Phase 1 |
| Completed | Neuromuscular Blockade in Patients With Severe Renal Impairment NCT03904550 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degree NCT04178577 | Spero Therapeutics | Phase 1 |
| Completed | A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How NCT05599997 | Bayer | Phase 1 |
| Terminated | A Renal Impairment Study for PF-06651600 NCT04037865 | Pfizer | Phase 1 |
| Completed | Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function NCT03961932 | ObsEva SA | Phase 1 |
| Completed | A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease NCT03913000 | Idorsia Pharmaceuticals Ltd. | Phase 1 |
| Completed | Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419 NCT05412472 | Galera Therapeutics, Inc. | Phase 1 |
| Completed | A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function NCT03890770 | Bristol-Myers Squibb | Phase 1 |
| Completed | Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients NCT03844555 | Genfit | Phase 1 |
| Completed | Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volun NCT03605277 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Renal Impairment Study for PF-04965842 NCT03660241 | Pfizer | Phase 1 |
| Terminated | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Fun NCT03639610 | Oncopeptides AB | Phase 2 |
| Completed | Lorlatinib Renal Impairment Study NCT03542305 | Pfizer | Phase 1 |
| Completed | Renal Biopsy Unexplained Elevated Serum Creatinine NCT03586531 | Assiut University | — |
| Terminated | Neurotoxic Adverse Effects of Morphine and Oxycodone for Pain in Terminal Patients With Diminished Renal Funct NCT03616639 | Maastricht University Medical Center | Phase 4 |
| Completed | Glasdegib Renal Impairment Study NCT03596567 | Pfizer | Phase 1 |
| Completed | Incidence of HANA Conditions in HIV-infected Individuals NCT03483584 | Chinese University of Hong Kong | — |
| Completed | Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK) NCT03436394 | Merck KGaA, Darmstadt, Germany | Phase 1 |
| Completed | Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients NCT03506854 | Akcea Therapeutics | Phase 1 |
| Completed | Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With N NCT03442725 | Ipsen | Phase 1 |
| Completed | Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Rena NCT03443063 | Eisai Inc. | Phase 1 |
| Unknown | Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease NCT03330054 | Mohammed Ramadan Abdallah | — |
| Completed | A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Si NCT03296787 | Takeda | Phase 1 |
| Completed | Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex NCT03284164 | ContraVir Pharmaceuticals, Inc. | Phase 1 |
| Completed | Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Re NCT03259087 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single NCT03235076 | Bayer | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Functi NCT03192111 | Syndax Pharmaceuticals | Phase 1 |
| Completed | A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Functio NCT03159416 | The Medicines Company | Phase 1 |
| Completed | Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. NCT03131479 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901 NCT02975388 | Hoffmann-La Roche | Phase 1 |
| Completed | Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment NCT02852239 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Single-Dose PK Study of GBT440 in Subjects With Renal Impairment NCT03161015 | Global Blood Therapeutics | Phase 1 |
| Completed | A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunc NCT02902679 | Bristol-Myers Squibb | Phase 1 |
| Completed | Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment NCT03289208 | Tanabe Pharma Corporation | Phase 1 |
| Completed | To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment NCT02942810 | Wockhardt | Phase 1 |
| Completed | A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subj NCT02813798 | GlycoMimetics Incorporated | Phase 1 |
| Completed | Accuracy and Treatment Experience of Two Glucose Monitoring Systems Tested in Patients With Type 1 Diabetes an NCT03378271 | Vastra Gotaland Region | N/A |
| Completed | A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairme NCT02709382 | Wockhardt | Phase 1 |
| Completed | A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment ( NCT02641067 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intrana NCT02606084 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function NCT02647918 | Lexicon Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment NCT02578082 | Mylan Inc. | Phase 1 |
| Completed | A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function NCT02399202 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function NCT03158792 | Lebanese American University | Phase 4 |
| Completed | Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function NCT02508506 | Alkermes, Inc. | Phase 1 |
| Withdrawn | An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclata NCT02397395 | Janssen R&D Ireland | Phase 2 |
| Completed | Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function NCT02442258 | AbbVie | Phase 1 |
| Completed | Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairm NCT02367872 | Takeda | Phase 1 |
| Completed | Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairme NCT02341599 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics NCT02286622 | PTC Therapeutics | Phase 1 |
| Completed | Prematurity as Predictor of Children's Cardiovascular-renal Health NCT02147457 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients NCT02214693 | Dong-A ST Co., Ltd. | Phase 1 |
| Terminated | A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficienc NCT01558674 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study Of Palbociclib (PD-0332991) In Renal Impairment NCT02085538 | Pfizer | Phase 1 |
| Completed | Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subj NCT02007941 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Completed | Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects NCT02084199 | Galapagos NV | Phase 1 |
| Completed | Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment. NCT02048787 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diasto NCT02058095 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systol NCT01970176 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers NCT02039817 | Conatus Pharmaceuticals Inc. | Phase 1 |
| Completed | Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616 NCT02011490 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin NCT01948986 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency NCT01937975 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment NCT02508740 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Rena NCT01904214 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects NCT01934166 | H. Lundbeck A/S | Phase 1 |
| Completed | EVP-6124 Renal Impairment Study NCT01984723 | FORUM Pharmaceuticals Inc | Phase 1 |
| Completed | Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment NCT02110459 | Polyphor Ltd. | Phase 1 |
| Completed | An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impai NCT01770652 | ApoPharma | Phase 4 |
| Completed | A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired NCT01761773 | Exelixis | Phase 1 |
| Completed | Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment NCT01763190 | Bristol-Myers Squibb | Phase 1 |
| Unknown | Renal Hypothermia During Partial Nephrectomy NCT01529658 | Ottawa Hospital Research Institute | N/A |
| Completed | Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impai NCT01575925 | Celgene | Phase 1 |
| Completed | Pharmacokinetics of LCQ908 in Patients With Renal Impairment NCT01558323 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Re NCT01578928 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes a NCT01555008 | Lexicon Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively NCT01526746 | Vanda Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics in Subjects With Renal Impairment NCT01504165 | Merck KGaA, Darmstadt, Germany | Phase 1 |
| Unknown | Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gou NCT05006001 | En Chu Kong Hospital | — |
| Completed | Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic NCT01464931 | Amgen | Phase 1 |
| Completed | A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function NCT01419041 | Pfizer | Phase 1 |
| Completed | A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects NCT02199379 | Eisai Inc. | Phase 1 |
| Completed | NAG-excretion During Cardiopulmonary Bypass NCT02410642 | Sahlgrenska University Hospital | — |
| Completed | Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB) NCT02405195 | Sahlgrenska University Hospital | — |
| Completed | A Pharmacokinetics and Safety Study in Subjects With Renal Impairment NCT01452828 | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function NCT01331941 | Amgen | Phase 1 |
| Completed | A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment NCT01443429 | Toray Industries, Inc | Phase 1 |
| Completed | Pharmacokinetics of BF2.649 in Renal Impairment NCT01619033 | Bioprojet | Phase 1 |
| Terminated | A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function NCT01359579 | Anthera Pharmaceuticals | Phase 1 |
| Unknown | CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation NCT01023542 | University of Regensburg | Phase 2 / Phase 3 |
| Completed | A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36 NCT01372124 | TME Pharma AG | Phase 1 |
| Completed | Safinamide Renal Impairment Trial NCT01374113 | Newron Pharmaceuticals SPA | Phase 1 |
| Completed | Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With NCT01372826 | AstraZeneca | Phase 1 |
| Completed | Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy NCT01459250 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With NCT01319266 | Cephalon | Phase 1 |
| Completed | Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impa NCT02244762 | Zogenix, Inc. | Phase 1 |
| Completed | Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Imp NCT01239459 | Sanofi | Phase 1 |
| Completed | To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Su NCT01240967 | AstraZeneca | Phase 1 |
| Completed | A Study of Fostamatinib in Subjects With Impaired Kidney Function NCT01245790 | AstraZeneca | Phase 1 |
| Completed | Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment NCT01613690 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in R NCT01148368 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847 NCT01141179 | LEO Pharma | Phase 1 |
| Terminated | Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bactere NCT01104662 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 4 |
| Completed | Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment NCT01082640 | Takeda | Phase 2 |
| Completed | Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Seve NCT01120314 | Sanofi | Phase 1 |
| Terminated | A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impai NCT00785772 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 |
| Completed | ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis NCT01083888 | Astellas Pharma Inc | Phase 1 |
| Completed | Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study NCT00706771 | Austin Health | Phase 2 |
| Completed | Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Norm NCT01028768 | Nycomed | Phase 1 |
| Terminated | Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairm NCT00984113 | Portola Pharmaceuticals | Phase 1 |
| Terminated | Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Se NCT00958269 | Phenomix | Phase 3 |
| Terminated | Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function NCT00879645 | Mallinckrodt | Phase 1 |
| Completed | Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialys NCT02596945 | Hoffmann-La Roche | — |
| Completed | A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With M NCT00999336 | Portola Pharmaceuticals | Phase 1 |
| Recruiting | Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes NCT00948116 | Barts & The London NHS Trust | — |
| Completed | Effect of Renal Impairment on the Pharmacokinetics of NN9535 NCT00833716 | Novo Nordisk A/S | Phase 1 |
| Terminated | Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed NCT00793182 | Guerbet | Phase 4 |
| Completed | Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients NCT00818571 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Safety of Gadovist in Renally Impaired Patients NCT00828737 | Bayer | Phase 4 |
| Completed | Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment NCT00828438 | Eisai Inc. | Phase 1 |
| Terminated | Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Fema NCT00787618 | Repros Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment NCT00768404 | VIVUS LLC | Phase 1 |
| Completed | A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment NCT00750620 | Astellas Pharma Inc | Phase 1 |
| Completed | The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases NCT00842868 | Massachusetts General Hospital | — |
| Completed | Safety Study of AZD5672 in Renally Impaired Subjects NCT00715702 | AstraZeneca | Phase 1 |
| Completed | Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function NCT01729364 | Sahlgrenska University Hospital | N/A |
| Terminated | Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment NCT00785551 | Mutual Pharmaceutical Company, Inc. | Phase 1 |
| Completed | Fanconi Syndrome Due to ARVs in HIV-Infected Persons NCT00499187 | Gilead Sciences | — |
| Completed | Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers NCT00733265 | AstraZeneca | Phase 1 |
| Withdrawn | Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography NCT00335101 | GE Healthcare | Phase 4 |
| Unknown | Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study NCT00852800 | Hospital de Clinicas de Porto Alegre | Phase 2 |
| Completed | Evaluating Patients With Varying Degrees of Renal Function NCT00398307 | Taiho Oncology, Inc. | Phase 1 |
| Completed | Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impai NCT00445302 | Genzyme, a Sanofi Company | Phase 1 |
| Completed | Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography NCT00209430 | GE Healthcare | Phase 4 |
| Completed | Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients NCT00652782 | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal NCT01796938 | UCB BIOSCIENCES GmbH | Phase 1 |
| Completed | A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function NCT00791401 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 |
| Completed | Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function NCT01367509 | Bausch Health Americas, Inc. | Phase 1 |
| Completed | Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function NCT01740362 | Pfizer | Phase 1 |
| Completed | Olmesartan Medoxomil in Hypertension and Renal Impairment NCT00151827 | Sankyo Pharma Gmbh | Phase 3 |
| Completed | Blood Products in Cardiac Surgery NCT02068755 | University of Turku | — |